ANTIOXIDANT (tempol) ALTERS GUT BACTERIA COMPOSITION RESULTING IN REDUCED OBESITY
The identification that the bacteria in our guts play
critical roles in whole body metabolic and immune homeostasis has led to an
explosion of scientific research in this field (intestinal microbiota) as well
as to increased interest in developing food products that can deliver
beneficial bacteria (probiotic) to the gut. I have written on this subject before
in my blog as well as discussed some of the details of how bacteria play a role
in the metabolic processes involved in the development of obesity and type 2
diabetes.
A recent paper, published in the journal Nature
Communications, demonstrates another highly interesting angle to the roles gut
microbiota play in the development of obesity and diabetes:
In this study the investigators expanded on an observation that
the antioxidant and radiation protectant molecule, tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine
1-oxyl), demonstrated an ability to prevent obesity in mice. Another related
study demonstrated that tempol administration was associated with an altered
metabolome (products of global metabolism) evidenced by alterations in
gut-derived metabolic compounds. Related information has previously shown a
correlation between the gut microbiome and their effects on metabolic pathways
elsewhere in humans such as bile acid and fatty acid metabolism. The two
predominant bacterial phyla in the human gut are Firmicutes and Bacteroidetes
and the relative abundance of these two populations have been shown to be
altered in obesity.
In the current study the investigators found that tempol
administration, in mouse chow, preferentially reduced the levels of bacteria
from the genus Lactobacillus (of the
Firmicutes phylum). Associated with the reduction in Lactobacillus was a decrease in the level of the bile salt
hydrolase (BSH) activity of this strain of bacteria. The reduced BSH activity
was associated with an increase in the gut level of the bile acid metabolite
tauro-beta-muricholic acid (T-b-MCA). T-b-MCA
is a known antagonist of the nuclear receptor: farnesoid X receptor (FXR). FXR
is a critical transcriptional co-regulator involved in the control of bile acid,
lipid, and glucose homeostasis. For more detailed information on the activities
of FXR go to the Farnesoid X Receptors page of my website.
The feeding of
tempol to experimental obese mice in this study was correlated to reduced levels
of obesity and reduced levels of insulin resistance even when the animal were
fed a high-fat diet. The increased insulin sensitivity observed in this study is
attributed to the tempol-induced reduction in obesity. Numerous studies in
rodents and humans have correlated increased insulin sensitivity to reductions
in fat content. Comparative analysis showed that intestine-specific FXR null
mice exhibited a reduced level of diet-induced obesity even when fed a high-fat
diet. Importantly, relative to the mode of action of tempol, is the fact that
this study also showed that tempol administration to the intestine-specific FXR
null mice did not further decrease weight gain. This demonstrates that the
effects observed as a result of tempol ingestion are due to gut-specific
responses to the drug not due to effects in other tissues as a result of the
absorption of tempol from the gut.
The take home from this study is that compounds like tempol may find utility in the
ongoing battle against obesity in humans. It should be pointed out that there
is still much work to be done to be able to fully (or even partially)
comprehend how we can manipulate the gut microbiome and what types of
manipulations should be made. In this study there was a distinct benefit to
reducing the level of the genus Lactobacillus
in effecting a positive change in obesity. However, other studies have shown
benefits to Lactobacillus. The
ingestion of Lactobacillus by
laboratory rodents has been associated with reduced anxiety and stress. In
addition, most probiotics sold at health food stores are predominantly composed
of strains of Lactobacillus.
The identification that the bacteria in our guts play critical roles in whole body metabolic and immune homeostasis has led to an explosion of scientific research in this field (intestinal microbiota) as well as to increased interest in developing food products that can deliver beneficial bacteria (probiotic) to the gut.
ReplyDeletetb 500 peptide